A Favorable Treatment Response of Erlotinib in Lung Adenocarcinoma with Concomitant Activating EGFR Mutation and ROS1 Rearrangement.
10.12771/emj.2014.37.1.46
- Author:
Min Hwan KIM
1
;
Yehyun PARK
;
Hye Jung PARK
;
Ah Young JI
;
Changho SONG
;
Moo Nyun JIN
;
Young Ju KIM
;
Sun Wook KIM
;
Jung Hee LEE
;
In Soo KIM
;
Hye Ryun KIM
;
Joohang KIM
;
Byoung Chul CHO
Author Information
1. Division of Medical Oncology, Yonsei Cancer Center, Seoul, Korea. cbc1971@yuhs.ac
- Publication Type:Case Report
- Keywords:
c-ros oncogene 1;
Epidermal growth factor receptor;
Non-small-cell lung carcinoma;
Erlotinib
- MeSH:
Adenocarcinoma*;
Brain;
Carboplatin;
Carcinoma, Non-Small-Cell Lung;
Disease-Free Survival;
Drug Therapy;
Female;
Humans;
Lung*;
Middle Aged;
Oncogenes;
Pleura;
Receptor, Epidermal Growth Factor;
Recurrence;
Small Cell Lung Carcinoma;
Erlotinib Hydrochloride;
Pemetrexed
- From:The Ewha Medical Journal
2014;37(1):46-51
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The rearrangement of c-ros oncogene 1 (ROS1) has been recently identified as an important molecular target in non small cell lung cancer (NSCLC). ROS1 rearrangement and epidermal growth factor receptor (EGFR) mutation were mutually exclusive each other in previous studies, and the clinical implication of co-existence of the two genetic alterations has not been determined. We report a case of 46-year-old female never-smoker NSCLC patient whose tumor harbored ROS1 rearrangement and EGFR mutation concomitantly. She had undergone curative surgery for stage IIIA NSCLC, and the recurrence in left pleura and brain occurred at 2 years after the surgery. She received several lines of chemotherapy including docetaxel plus carboplatin, erlotinib, pemetrexed, and gemcitabine. Erlotinib therapy showed a favorable treatment response with progression-free survival of 9.5 months and partial response of tumor on radiologic evaluations. This case represents a successful erlotinib treatment in a NSCLC patient with concurrent ROS1 rearrangement and EGFR mutation.
